The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.
Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.
The decision to halt trials for the uterine fibroid product marks another setback in an area where there are few suitable solutions for patients.